Author: Charmaine Fraser

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that so far this month, it has secured multiple new contract awards with a combined value of over £345,000.   The awards comprise a combination of new and follow-on engagements with respected UK and international biotechnology and oncology-focused organisations, including...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that Peter Sargent has agreed to extend his existing agreement with the Company and remain in his current role throughout June 2026.   The Board and Dr Sargent remain in ongoing discussions regarding a potentially longer-term continuation of his involvement,...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the appointment of Stewart Williams FCILT as a consultant to the Company.   Mr Williams will support the Board and management team during the Company’s senior leadership transition, providing strategic, operational and programme delivery expertise to assist with the ongoing...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that the newly appointed Board has commenced an extensive review of the business with a clear focus on operational optimisation, commercial execution, and shareholder value creation.   The Board believes the Company possesses a number of underappreciated strengths, including an...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces that all resolutions (“Resolutions”) put to shareholders at the general meeting, called by Mr Michael Whitlow, held today (“General Meeting”) were passed.   Click here to read in full...

The following amendment has been made to the 'Results of General Meeting and Board Changes' announcement released on 29 April 2026 at 11:00 under RNS No 4220C.   Addition of “Jim Millen” to the list of the directors who have been removed from the Board with immediate effect in the second paragraph, in accordance with the Resolutions. All other details remain unchanged.   Click here to read in full...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces the launch of a dedicated website aimed at providing key information to shareholders considering their vote in relation to the Company's forthcoming Requisitioned General Meeting to be held at 10.00 a.m. on 29 April 2026 ("Requisitioned General Meeting").   The website is available...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its valued and long-standing client, Numab Therapeutics AG (“Numab Therapeutics”).   Numab Therapeutics is a biopharmaceutical company focused on the discovery and development of next-generation multispecific antibody-based therapeutics for inflammation and oncology. Under this new contract,...